(Reuters) – The U.S. Food and Drug Administration said on Wednesday it approved Merck & Co Inc’s Keytruda for the treatment of a type of bladder cancer. The therapy was approved for patients with a high-risk non-muscle invasive bladder cancer who are ineligible for or have opted out of surgical removal of part of the bladder.

Reporting by Saumya Sibi Joseph in Bengaluru; Editing by Aditya Soni